What is Access Vascular?
Founded in 2015 and headquartered in Massachusetts, Access Vascular specializes in the development of advanced medical devices, with a primary focus on catheters engineered from proprietary biomaterials. By addressing the critical clinical challenges of catheter-related complications, such as thrombosis and phlebitis, the company provides high-performance solutions that improve patient outcomes. Their market position is defined by a commitment to material science innovation, which differentiates their product portfolio from traditional polymer-based medical devices. As the demand for safer, more durable vascular access tools grows, Access Vascular remains at the forefront of clinical engineering, leveraging its unique material science platform to capture significant market share in the healthcare sector.
How much funding has Access Vascular raised?
Access Vascular has raised a total of $51.7M across 4 funding rounds:
Series A
$3.7M
Unspecified
$6M
Series B
$20M
Series C
$22M
Series A (2017): $3.7M with participation from angelMD
Unspecified (2019): $6M, investors not publicly disclosed
Series B (2021): $20M supported by TVM Capital GmbH
Series C (2023): $22M, investors not publicly disclosed
Key Investors in Access Vascular
angelMD
A specialized investment platform and community that connects medical startups with a network of physicians and industry experts to drive clinical innovation.
TVM Capital GmbH
A venture capital firm with a long-standing history of investing in life sciences, healthcare, and medical technology companies across global markets.
Undisclosed Investor
An undisclosed institutional partner participating in the latest strategic financing round to support the company's long-term growth objectives.
What's next for Access Vascular?
With the successful closure of its latest financing round, Access Vascular is well-positioned to accelerate its commercial expansion and research initiatives. The strategic deployment of this capital will likely focus on scaling production capacity to meet increasing clinical demand and advancing the regulatory approval process for its next-generation product pipeline. Furthermore, the company is expected to strengthen its market presence by expanding its sales infrastructure and deepening its engagement with healthcare providers. As the firm moves into this next phase of growth, the focus will remain on maintaining its competitive edge through continuous innovation in biomaterial science, ensuring that its medical devices remain the preferred choice for clinicians seeking to reduce complications and enhance the efficiency of vascular access procedures.
See full Access Vascular company page
